Personalized Treatment for Recurrent Ovarian, Cervical or Endometrial Cancer
Studies gene testing and expert team advice to guide treatment in recurring gynecological cancers.
Plain-language title generated from the registry record
Registry title: A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
Key facts
- Where
- Guangzhou and Shenzhen, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women whose ovarian, cervical or endometrial cancer has come back and who are referred for a team consultation. Tumor tissue is tested to guide treatment.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Recurrent ovarian, cervical or endometrial cancer, with at least one lesion that can be measured
- Biomarker or test result
- Enough tumor tissue for next-generation sequencing (NGS), with tumor content greater than 32%
Main reasons for not taking part
- Another cancer at the same time
- Pregnancy
Read by machine on 9 November 2026.
Where in China
- Sun Yat-sen University Cancer CenterGuangzhou, ChinaTaking people
- Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen CenterShenzhen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-sen University
- Trial code
- NCT06781151
- Record updated
- 27 August 2025
- Original description
This is a non-interventional, real-world study divided into two parts: a retrospective study and a prospective study.Read full original descriptionShow less
A Real-world Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on Molecular Profiling and Multidisciplinary Team Consultation
This is a non-interventional, real-world study divided into two parts: a retrospective study and a prospective study.
The main question it aims to answer is:
Will genomic sequencing and molecular tumor boards lead to clinical responses in patients with recurrent ovarian, cervical, or endometrial cancer? The retrospective arm will analyze data from patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) who underwent multidisciplinary consultations at our institution from January 2022 onward. Data collected will include tumor tissue genomic sequencing results, medical histories, multidisciplinary consultation recommendations, and subsequent treatment courses. This analysis will examine the implementation and clinical efficacy of personalized targeted therapies guided by molecular tumor profiling and multidisciplinary consultation.
The prospective arm will enroll 200 patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) referred for multidisciplinary consultation. Tumor tissue and blood samples will undergo next-generation sequencing (NGS) to determine molecular tumor profiles. A multidisciplinary expert panel will formulate individualized treatment strategies based on these profiles, patient clinical data, and treatment history. Attending physicians will determine the final treatment plan, integrating multidisciplinary recommendations with patient preferences, comorbidity considerations, drug toxicity assessments, insurance coverage for off-label medications, and the availability of investigational drug trials. This arm aims to observe and evaluate the clinical efficacy of personalized treatment plans developed through molecular tumor profiling and multidisciplinary consultation.
Inclusion: Patients with recurrent ovarian, cervical, or endometrial cancer referred for multidisciplinary consultation by a gynecological oncologist; Presence of at least one evaluable lesion; Willingness to participate in multidisciplinary consultation; Age 18 years or older; Sufficient tumor tissue for next-generation sequencing (NGS) with a tumor content greater than 32%; Informed consent provided by the participant, indicating understanding of the study procedures and willingness to participate.
Exclusion: Patients with concurrent malignancies; Pregnant patients.